It has demonstrated significant improvements in glycemic control and insulin sensitivity in T2DM and the safety profile is well‐established, particularly in pediatric populations, with lower adverse effects compared to other SGLT2 inhibitors [4, 13, 32, 48]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.